Logo

NTRBW

Nutriband Inc.

NTRBW

Nutriband Inc. • NASDAQ
$1.20 ▼ -14.29% (-0.20)
Market Cap $13.39 M
52w High $5.25
52w Low $1.00
Dividend Yield 0%
P/E -2.38
Volume 642
Outstanding Shares 11.16M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $622.452K ▼ $2.16M ▲ $-2M ▼ -321.364% ▼ $-2.12 ▼ $-1.946M ▼
Q1-2025 $667.432K ▲ $1.657M ▼ $-1.389M ▲ -208.111% ▲ $-0.12 ▲ $-1.326M ▲
Q4-2024 $642.379K ▼ $2.238M ▲ $-5.516M ▼ -858.683% ▼ $-0.51 ▼ $-5.44M ▼
Q3-2024 $645.796K ▲ $1.606M ▲ $-1.363M ▲ -211.057% ▲ $-0.12 ▲ $-1.285M ▲
Q2-2024 $442.83K $1.501M $-1.705M -385.024% $-0.15 $-1.63M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $6.995M ▲ $10.177M ▲ $1.683M ▲ $8.494M ▲
Q1-2025 $2.964M ▼ $6.152M ▼ $1.049M ▲ $5.103M ▼
Q4-2024 $4.312M ▼ $7.47M ▼ $1.041M ▼ $6.429M ▼
Q3-2024 $5.698M ▼ $12.543M ▼ $1.312M ▲ $11.232M ▼
Q2-2024 $6.76M $13.634M $1.173M $12.461M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-2M ▼ $-1.313M ▲ $5.324K ▲ $5.344M ▲ $4.031M ▲ $-1.308M ▲
Q1-2025 $-1.389M ▲ $-1.337M ▼ $-5.324K ▼ $-5.326K ▲ $-1.348M ▲ $-1.337M ▼
Q4-2024 $-5.516M ▼ $-1.239M ▼ $0 ▲ $-147.224K ▼ $-1.386M ▼ $-1.239M ▼
Q3-2024 $-1.363M ▲ $-1.01M ▲ $-46.958K ▼ $-5.175K ▼ $-1.062M ▲ $-1.057M ▲
Q2-2024 $-1.705M $-1.544M $-38.89K $-5.136K $-1.588M $-1.583M

Five-Year Company Overview

Income Statement

Income Statement Nutriband looks like a very early-stage, development-focused company with essentially no meaningful revenue yet. The business is running at a loss, which is typical for a biotech in the research and pre-commercial phase. Recent years show persistent negative earnings per share, suggesting that shareholders are being diluted by ongoing operating and R&D costs without offsetting sales so far. Overall, the income statement tells a story of a company still firmly in the investment and build-out stage rather than one in a commercialization or profit phase.

Balance Sheet

Balance Sheet The balance sheet appears very small and simple, with modest assets, no reported debt, and equity making up nearly all of the capital base. This suggests a lean operation but also limited financial resources to absorb setbacks or delays. The absence of debt reduces pressure from interest payments, yet it also implies that the company may rely heavily on raising new equity or partnerships to fund future work. In short, the balance sheet is clean but thin, which raises both flexibility and fragility considerations.

Cash Flow

Cash Flow The cash flow data shown are flat, which likely reflects limited operating scale and early-stage spending patterns rather than mature business dynamics. With no real revenue yet, cash generation from operations is not in focus; instead, the key issue is how long existing cash can cover development costs and how easily the company can access new funding. Investment in physical assets appears minimal, consistent with a light, research-driven model. Overall, the cash-flow picture underlines the importance of future capital-raising and milestone payments from partners, rather than internal cash generation, for now.

Competitive Edge

Competitive Edge Nutriband is trying to build a niche around safer transdermal drug delivery, especially for drugs with abuse potential like opioids. Its AVERSA abuse-deterrent patch technology, combined with patents across many countries and a partnership with an experienced manufacturer, gives it a potential edge if the products reach market. Being an early mover in abuse-deterrent fentanyl patches could help establish a recognizable standard in that area. However, the company is still pre-commercial, so its competitive strength is mainly on paper—patents, technology, and partnerships—rather than proven market share.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Nutriband’s story. The AVERSA platform is designed to make drug patches harder to misuse while not interfering with the medicine itself, which addresses a well-known safety problem. The company is also extending this approach to other drugs and exploring broader transdermal applications, helped by in-house R&D and manufacturing capabilities. The upside is meaningful if clinical and regulatory milestones are met, but the usual biotech risks apply: scientific, regulatory, timing, and funding uncertainty remain high.

Summary

Nutriband is essentially a small, research-stage biotech platform focused on safer drug patches, with almost no current revenue and steady losses, supported by a thin but debt-free balance sheet. The investment case rests on its AVERSA abuse-deterrent technology, strong patent coverage, strategic partnership with a specialist manufacturer, and a pipeline that reuses the same core platform across multiple drugs. Execution risk is significant: the company still needs to clear clinical and regulatory hurdles and then prove real-world adoption and pricing power. Overall, this looks like a high-uncertainty, high-dependence-on-milestones story typical of early-stage biotech rather than a mature operating business at this point.

NEWS

November 24, 2025 · 7:00 AM UTC

Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference

Read more

October 28, 2025 · 11:05 AM UTC

REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch

Read more

October 28, 2025 · 7:00 AM UTC

Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch

Read more

October 10, 2025 · 7:00 AM UTC

Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch

Read more

October 8, 2025 · 8:30 AM UTC

Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology

Read more